



Tasmar

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
T/0066	Transfer of Marketing Authorisation	28/10/2022	21/11/2022	SmPC, Labelling and PL	
PSUSA/2985/202103	Periodic Safety Update EU Single assessment - tolcapone	28/10/2021	n/a		PRAC Recommendation - maintenance

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



IB/0064	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	24/09/2020	19/10/2021	SmPC, Annex II, Labelling and PL	
IA/0063	A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient	25/05/2020	n/a		
IB/0062/G	This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.c.1.a - Change in immediate packaging of the AS - Qualitative and/or quantitative composition B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	17/05/2019	n/a		
II/0061	Submission of an updated RMP version 7.0 in order to: - reflect currently available data from post-marketing experience and patient exposure data; - align the RMP with the new GVP RMP template rev.2; - remove the important identified risk	14/02/2019	n/a		

	<p>'dopaminergic effects due to increased bioavailability of co-administered levodopa (e.g. dyskinesia)' and the potential risks 'drug interactions with significant clinical consequence including sudden sleep onset', 'melanoma' and 'intense urges';</p> <ul style="list-style-type: none"> - revise the targeted follow-up questionnaire for hepatic events and the Patient Diary. <p>C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required</p>				
PSUSA/2985/201803	Periodic Safety Update EU Single assessment - tolcapone	04/10/2018	n/a		PRAC Recommendation - maintenance
IB/0060	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	08/08/2018	26/08/2019	Labelling and PL	
IA/0058	B.I.a.3.b - Change in batch size (including batch size ranges) of AS or intermediate - Downscaling down to 10-fold	15/06/2017	n/a		
IA/0057	A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient	16/05/2017	n/a		

IA/0056	B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State	22/09/2016	n/a		
IA/0055	B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State	12/08/2016	n/a		
N/0054	Update of the package leaflet with revised contact details of the local representatives for Spain and France. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	06/07/2016	22/08/2016	PL	
IA/0053	B.II.e.5.b - Change in pack size of the finished product - Deletion of a pack size(s)	06/11/2015	22/08/2016	SmPC, Labelling and PL	
PSUSA/2985/ 201503	Periodic Safety Update EU Single assessment - tolcapone	08/10/2015	n/a		PRAC Recommendation - maintenance
IAIN/0052	B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes	14/08/2015	22/08/2016	SmPC, Labelling and PL	

IA/0050	A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient	25/06/2015	n/a		
R/0047	Renewal of the marketing authorisation.	22/05/2014	18/07/2014	SmPC, Annex II, Labelling and PL	Tolcapone is indicated in combination with levodopa/benserazide or levodopa/carbidopa for use in patients with levodopa-responsive idiopathic Parkinson's disease and motor fluctuations, who fail to respond to or are intolerant of other catechol-O-methyltransferase (COMT) inhibitors. Based on a safety data collected since the time of last renewal and the known efficacy of Tasmar the CHMP considered that the benefits of the product continue to outweigh the risks and therefore recommended the renewal of the marketing authorisation with unlimited validity.
N/0048	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	16/02/2014	05/03/2014	PL	
IB/0046/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS A.7 - Administrative change - Deletion of manufacturing sites B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time	27/08/2013	n/a		

	<p>data</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p>				
IG/0277	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	26/03/2013	n/a		
IB/0044	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	06/03/2013	05/03/2014	SmPC and Annex II	Annex I (SmPC) and Annex II of the product information was brought in line with the latest QRD template. Annex II has been updated in line with revision 3 of QRD template version 8.
IB/0043	C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH	17/10/2012	29/10/2012	SmPC and PL	<p>Following CHMP conclusions from 19 July 2012 the product information (PI) has been updated in line with the recommendations in relation to impulse control disorders for products containing levodopa, dopamine agonists and/or COMT inhibitor and the risk of impulse control disorders.</p> <p>Additionally, the address of the local representative in Greece has been updated.</p>
IB/0042	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	06/02/2012	21/03/2012	SmPC, Annex II, Labelling and PL	The scope of this variation is to bring the Annex II and Annex III of the current Product Information in line with the latest version of the QRD template (August 2011). Minor editorial changes have been introduced in Annex I. In addition, the Annex IIIB has been amended following the results of a User Testing, and the local representatives section has been updated.
IB/0041	B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g.	17/08/2011	17/08/2011	SmPC, Labelling and	

	tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes			PL	
IB/0040	B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation	28/04/2011	n/a		
R/0039	Renewal of the marketing authorisation.	23/07/2009	02/10/2009	SmPC, Annex II, Labelling and PL	<p>Based on the review of the available information the CHMP is of the opinion that the quality, the safety and the efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considers that the benefit/risk profile of Tasmar continues to be favourable., but considers that its safety profile is to be closely monitored for the following reasons:</p> <ul style="list-style-type: none"> - Since the lifting of the suspension there has been a relatively limited exposure in Europe. The CHMP also noted that this is effectively the first renewal since the lifting of the suspension. - Specific measures are still in place in relation to be monitoring of particular safety issues including hepatotoxicity and NMS, also remaining submission of yearly PSURs <p>Therefore, the CHMP concluded that the MAH should submit one additional renewal application in 5 years time. Intense urges has been added to the section 4.4 of the SPC on the basis of the data submitted with the renewal dossier.</p>
T/0038	Transfer of Marketing Authorisation	22/01/2009	13/02/2009	SmPC, Labelling and PL	

N/0037	Update of the list of local representatives in section 6 of the Package Leaflet. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	10/04/2008	n/a	PL	
IA/0036	IA_08_b_02_Change in BR/QC testing - repl./add. manuf. responsible for BR - incl. BC/testing	06/03/2008	n/a	Annex II and PL	
IB/0032	IB_07_c_Replacement/add. of manufacturing site: All other manufacturing operations ex. batch release	04/03/2008	n/a		
IA/0035	IA_07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms	27/02/2008	n/a		
IA/0034	IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site	27/02/2008	n/a		
IA/0029	IA_05_Change in the name and/or address of a manufacturer of the finished product	12/02/2008	n/a		
N/0028	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	14/03/2007	n/a	PL	
II/0027	This application refers to an update of Sections 4.4 (Special warnings and Special Precautions for Use) of the Summary of Product Characteristics (SPC) further to CHMP recommendation following assessment of the 12th PSUR. In addition, section 4.8 of the SPC has been revised in accordance to the SPC guideline.	28/06/2006	04/08/2006	SmPC	Further to the assessment of the 12th PSUR for Tasmar, the CHMP requested that the Marketing Authorisation Holder (MAH) updated the Summary of Product Characteristics (SPC) to refer to the possibility of late onset hepatitis. The CHMP request follows the publication of a case of late onset hepatitis (approximately 18 months after the start of tolcapone treatment).

	Update of Summary of Product Characteristics				The MAH therefore applied for an update of Section 4.4 (Special warnings and Special Precautions for Use) to reflect the CHMP recommendation. Additionally, section 4.8 (Undesirable Effects) has also been updated to bring it in line with the latest SPC guideline on presentation of the information on adverse drug reactions.
IB/0026	IB_42_a_01_Change in shelf-life of finished product - as packaged for sale	22/12/2005	n/a	SmPC	
IA/0025	IA_08_b_01_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing	20/12/2005	n/a	Annex II and PL	
IA/0024	IA_05_Change in the name and/or address of a manufacturer of the finished product	20/12/2005	n/a		
IA/0023	IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size	19/07/2005	19/07/2005	SmPC, Labelling and PL	
II/0021	Change(s) to the manufacturing process for the active substance Change(s) to the test method(s) and/or specifications for the active substance	16/03/2005	23/03/2005		
N/0022	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	14/03/2005	n/a	PL	
IB/0017	IB_33_Minor change in the manufacture of the finished product	28/02/2005	n/a		

IB/0019	IB_10_Minor change in the manufacturing process of the active substance	08/02/2005	n/a		
IB/0018	IB_10_Minor change in the manufacturing process of the active substance	08/02/2005	n/a		
IA/0020	IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site IA_07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms	13/01/2005	n/a		
IA/0016	IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)	13/01/2005	n/a		
T/0014	Transfer of Marketing Authorisation	25/11/2004	22/12/2004	SmPC, Annex II, Labelling and PL	
IA/0015	IA_09_Deletion of manufacturing site	03/11/2004	n/a		
IA/0013	IA_08_b_01_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing	15/09/2004	n/a	Annex II and PL	
IA/0012	IA_39_Change/addition of imprints, bossing or other markings	15/09/2004	n/a	SmPC and PL	
Z/0011	On 16 February 2004, the Marketing Authorisation Holder submitted documentation to support the review of the suspension of the Tasmar Marketing Authorisation, addressing the issues raised by CPMP during its October 2003 plenary meeting. This submission complements the supplementary	22/04/2004	31/08/2004	SmPC, Annex II, Labelling and PL	

	information provided by the MAH on 15 July 2003, as part of the review of the suspension of the Marketing Authorisation.				
Z/0010		22/10/2003	14/01/2004		
Z/0009		19/09/2002	07/01/2003		
Z/0008		19/09/2001	17/12/2001		
Z/0007		19/10/2000	29/01/2001		
Z/0006		21/10/1999	20/01/2000		
Z/0005		12/11/1998	11/12/1998		
II/0004	New safety warning	21/10/1998	n/a	SmPC and PL	
I/0003	01_Change following modification(s) of the manufacturing authorisation(s)	24/04/1998	n/a	Annex II and PL	
I/0001	12_Minor change of manufacturing process of the active substance	25/11/1997	n/a		
I/0002	20_Extension of shelf-life as foreseen at time of authorisation	28/10/1997	n/a	SmPC	